ICH Q11 Q&A - A Supporting Document for the Selection and Justification of Starting Materials
FDA discusses key concepts and clarification for starting materials selection based on ICH Q11 Q&A. Presenter: Anita Tiwari, Division of Lifecycle API Learn more at: https://www.fda.gov/drugs/news-events... -------------------- FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research. Upcoming Training - https://www.fda.gov/cdersbia SBIA Listserv - https://public.govdelivery.com/accoun... SBIA 2021 Playlist - • 2021 CDER Small Business and Industry Assi... SBIA LinkedIn: / cder-small-business-and-industry-assistance SBIA Training Resources - https://www.fda.gov/cdersbialearn Twitter - / fda_drug_info Email - [email protected] Phone - (301) 796-6707 I (866) 405-5367

Process Validation and ICH Q7

Pharmacovigilance in Practice From Safety Signals to Regulatory Action 1080

Drug Substance Facilities – Hidden and Critical Intermediate

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

April 30, 2026 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

Drug Master File (DMF) Submissions on New FDA Form 3938

VRBPAC -- May 28 Meeting

Investigational New Drug (IND) Submission: Content/Format and First 30 Days (5of14) REdI 2018

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Evaluation of Metal Impurities in Drug Substances

FDA Direct - Special Edition of FDA Direct

FDA Direct: The Power of Real-Time Clinical Trials

OTC Monograph Reform: OTC Sunscreen Drugs

ClinicalTrials.gov: Essentials for Academic Medical Centers – Pre-recorded Training Video

ICH Q12 Guidance and Emerging Technology Program (11of16) Generic Drugs Forum 2020

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

